Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Cethromycin Experts

Articles with lock require a subscription to GLG News | Request a free trial
Joseph BertinoSeptember 23, 2008
Gene Targeted Drug Therapy for Heart Failure
Analysis of: Gene Targeted Drug Therapy for Heart Failure | www.bio-medicine.org
Author: Joseph Bertino, Independent Consultant, Bertino Consulting
-Another step towards invididualized medicine -Proves that old drugs can be reinvented for useful purposes -Advances pharmacogenetics forward
September 15, 2008
Velcade has multiple efficcay
Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Author: GLG Expert Contributor
It is very good news atht Velcade approved for previously untreated multiple Myeloma. Velcade has multiple efficacy as treatmnet is concerned for other diseases too ( Diabetes-II, Cardiovascular disease) as the mechanism of action is same for those target ( proteasome  inhibitors).
September 11, 2008
Onglyza (saxagliptin) has a great scope for Diabetes-II
Analysis of: BMS, AstraZeneca present saxagliptin data | www.fiercebiotech.com
Author: GLG Expert Contributor
Saxagliptin has good positive resluts in Phase-III trial.Still noe there i snor side effect reported. Thsi drug will compete  with Januvia ( merck). But Saxagliptin is better situtaion as the mechanism of action is concerned on DPP-4.
August 29, 2008
This is bad news for Cell Genesys but may use for other treatment
Analysis of: Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
Author: GLG Expert Contributor
 1. Radioimmunoassay is very hard to  proof the basic biology of metastatic patient. 2.  GVAX  Immunotherapy is basically modify the  GM-CSF, so the exact biology of immune system of the patient  should be considered in metastatic stage before use. As the tumor is already...
August 26, 2008
Temozolomide and Thalidomide combination therapy for Malignant Melanoma
Analysis of: Temozolomide And Thalidomide Combination Effective Against Malignant Melanoma Spread To CNS And White Blood Cell Count May Be Prognostic | www.medicalnewstoday.com
Author: GLG Expert Contributor
1.  The phase II clinical trial  of the combination thherapy of ( temozolomide and Thalidomide for Malignant Melanoma is very encourganing. It may open new avenue to treat   malignant melanoma  affecting Brain. 2. This  article is important for use  of combination...
August 22, 2008
The FInal Cervical cancer Vaccine is media hype
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
Author: GLG Expert Contributor
1.  Merck and GSK are pushing too much for Cerival cancer vaccine advertisement. 2.  Merck ( Gardasil), and GSK( cervarix) are very tiny age applications, but real disease start after 20, so early vaccination is no use, but Pap smear is more helpful 3. So drug marker push to cancer vaccine lead...
August 21, 2008
There is a hope for NHL ( Non-Hodgkin's Lymphoma).
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: GLG Expert Contributor
1. BiovaxID®  is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. 2. Unlike many other approaches...
August 19, 2008
Byetta sale will reduce after FAD alert
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
Author: GLG Expert Contributor
 1. As Byetta is not monotherapy and the clinical trial results  are  not clear about the condition od trial patient, so future of Byetta is  blink
Joseph BertinoAugust 15, 2008
Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware?
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: Joseph Bertino, Independent Consultant, Bertino Consulting
-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales
August 14, 2008
Imaging and therapeutic agents for Brain tumor ( glioblastoma multiforme)
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor
1.  Public awareness and budget for research for brain will increase. 2. Federal      funding  should increase for GBM ( Glioblastoma multiforme) 3. More researchers will join in this field

Page : 1 2 3 Next1 to 10 of 22

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747